著者

Shoken ISHII Philippe BARON Makoto AOKI Kohei MIZUTANI Motoaki YASUI Satoshi OCHIAI Atsushi SATO Yohei SATOH Takuji KUBOTA Daisuke SAKAIZAWA Riko OKI Kozo OKAMOTO Toshiyuki ISHIBASHI Taichu Y. TANAKA Tsuyoshi T. SEKIYAMA Takashi MAKI Koji YAMASHITA Tomoaki NISHIZAWA Masaki SATOH Toshiki IWASAKI

出版者

(公社)日本気象学会

雑誌

気象集誌. 第2輯 (ISSN:00261165)

巻号頁・発行日

vol.95, no.5, pp.301-317, 2017 (Released:2017-10-04)

参考文献数

57

被引用文献数

15

---

A working group is studying the feasibility of a future Japanese space-borne coherent Doppler wind lidar (CDWL) for global wind profile observation. This study is composed of two companion papers: an instrumental overview of the space-borne CDWL for global wind profile observation (Part 1), and the wind measurement performance (error and bias) investigated using a full-fledged space-borne CDWL simulator (Part 2). This paper aims to describe the future space-borne CDWL in terms of technical points and observation user requirements. The future mission concept is designed to have two looks for vector wind measurement with vertical resolutions of 0.5 (lower troposphere: 0-3 km), 1 (middle troposphere: 3-8 km), and 2 km (upper troposphere: 8-20 km) and horizontal resolution of < 100 km along a satellite. The altitude and orbit of the satellite are discussed from a scientific viewpoint. The candidate altitude and orbit of the satellite are 220 km and an inclination angle of 96.4° (polar orbit) or 35.1° (low-inclination-angle orbit). The technical requirements of the space-borne CDWL are a single-frequency 2-μm pulse laser with an average laser power of 3.75 W, two effective 40-cm-diameter afocal telescopes, a wide-bandwidth (> 3.4 GHz) detector, a high-speed analog-to-digital converter, and a systematic lidar efficiency of 0.08. The space-borne CDWL looks at two locations at a nadir angle of 35° at two azimuth angles of 45° and 135° (225° and 315°) along the satellite track. The future space-borne CDWL wind profile observation will fill the gap of the current global wind observing systems and contribute to the improvement of the initial conditions for numerical weather prediction (NWP), the prediction of typhoons and heavy rain, and various meteorological studies.

著者

Hidenori Arai Hideaki Bujo Daisaku Masuda Toshiyuki Ishibashi Satoshi Nakagawa Kenichiro Tanabe Tatsuo Kagimura Hyun-Jae Kang Moo Hyun Kim Jidong Sung Sang-Hyun Kim Cheol-Ho Kim Jeong Euy Park Junbo Ge Byung-Hee Oh Toru Kita Yasushi Saito Masanori Fukushima Yuji Matsuzawa Shizuya Yamashita

出版者

Japan Atherosclerosis Society

雑誌

Journal of Atherosclerosis and Thrombosis (ISSN:13403478)

巻号頁・発行日

pp.62821, (Released:2021-04-18)

参考文献数

45

被引用文献数

6

---

Aims: In this study, we integrated two randomized control trials, PROSPECTIVE and IMPACT, to address the effect of probucol on cerebrocardiovascular events and carotid intima-media thickness (IMT) in Japanese, Korean, and Chinese patients with coronary artery disease (CAD). Methods: A total of 1,025 patients from the PROSPECTIVE and IMPACT studies were enrolled. The time to the first major adverse cerebrocardiovascular event, in addition to carotid IMT and lipid levels, was compared between the control and probucol groups. Results: In the integrated analysis, the adjusted hazard ratio (HR) and 95% confidence interval (CI) were 0.67 and 0.44–1.03, respectively, indicating a tendency to show the effect of probucol on cerebrocardiovascular events in secondary prevention. We also found no significant differences between the control and probucol groups in the mean IMT of the carotid arteries and its changes. However, we found a significant decrease in cerebrocardiovascular events in patients with reduced levels of HDL cholesterol (HDL-C) (≥ 6.25 mg/dL) compared with those with levels <6.25 mg/dL (p=0.024), without any increase in adverse events such as severe ventricular arrhythmias. Conclusion: We demonstrated a marginal effect of probucol on cerebrocardiovascular events in Asian patients with CAD, with reasonable safety profiles. A larger study may be needed to support the effect of probucol for cardiovascular prevention.

著者

Shizuya Yamashita Hidenori Arai Hideaki Bujo Daisaku Masuda Tohru Ohama Toshiyuki Ishibashi Koji Yanagi Yasuji Doi Satoshi Nakagawa Koichi Yamashiro Kenichiro Tanabe Toru Kita Masunori Matsuzaki Yasushi Saito Masanori Fukushima Yuji Matsuzawa on Behalf of the PROSPECTIVE Study Group

出版者

Japan Atherosclerosis Society

雑誌

Journal of Atherosclerosis and Thrombosis (ISSN:13403478)

巻号頁・発行日

pp.55327, (Released:2020-04-24)

参考文献数

50

被引用文献数

26

---

Aims: Although intensive statin therapy reduced cardiovascular risks, cardiovascular events have not been completely prevented. Probucol is a potent antioxidant and reduces tendon xanthomas in familial hypercholesterolemia patients despite reduction of high-density lipoprotein (HDL)-cholesterol (HDL-C). We investigated whether probucol can reduce cardiovascular events on top of conventional lipid-lowering therapy in patients with coronary heart disease (CHD). Methods: PROSPECTIVE is a multicenter, randomized, prospective study that recruited 876 Japanese patients with CHD and dyslipidemia with an low-density lipoprotein (LDL)-cholesterol (HDL-C) level of ≥ 140 mg/dL without medication or those treated with lipid-lowering drugs. Lipid-lowering agents were administered during the study period in the control group (n=438), and probucol 500 mg/day was added to lipid-lowering therapy in the probucol group (n=438). Patients were randomly assigned to two treatment groups by adjusting the LDL-C level and presence of diabetes and hypertension and followed up for more than 3 years. The primary end point was a composite of cerebrovascular and cardiovascular events (cardiovascular disease death including sudden death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina, hospitalization for heart failure, or coronary revascularization). The secondary end point was carotid intima–media thickness in a subset of patients. Results: The incidence of the primary end point showed a trend to be lower in the probucol group compared with that in the control group despite reduced HDL-C without serious adverse events. Anti-atherogenic effects of probucol may be attributed to its potent antioxidative function and enhancement of reverse cholesterol transport. Conclusion: Since there was no statistical significance between the probucol and control groups despite a marked reduction of HDL-C, further studies on the clinical outcomes of probucol on top of conventional therapy may be necessary in the future (UMIN000003307).